FDA advisers endorse gene therapy to treat form of blindness

  • Oct. 12, 2017 2:56 p.m.

SILVER SPRING, Md. — A potentially groundbreaking treatment for a rare form of blindness moved one step closer to U.S. approval Thursday, as federal health advisers endorsed the experimental gene therapy for patients with an inherited condition that gradually destroys eyesight.

The panel experts to the Food and Drug Administration voted unanimously in favour of Spark Therapeutics’ injectable therapy, which aims to improve vision by replacing a defective gene needed to process light.

The vote amounts to a recommendation to approve the therapy. The FDA has until mid-January to make its decision and does not have to follow the panel’s recommendation, though it often does.

If approved, Luxturna would be the first gene therapy in the U.S. for an inherited disease and the first in which a corrective gene is given directly to patients. While the therapy from Spark Therapeutics targets a small group of patients — about 2,000 in the U.S. — experts say it could pave the way for other genetic treatments for a variety of inherited conditions.

Panelists debated several specifics of the treatment, splitting on whether to require a minimum age for treatment; the company says the drug is intended for those 3 years and older. Panelists concluded that the science behind the drug — based on research from the Children’s Hospital of Philadelphia — was remarkably strong with few serious side effects.

Several patients attended the meeting to urge panelists to support the drug, relating experiences of seeing snow, stars and the moon for the first time. In most cases, the patients’ travel expenses were paid for by the drug’s developer.

Katelyn Corey, 24, described her life before the treatment as “a black and white film.”

“Within days of the first treatment I could see vibrant colours again,” Corey said. “I could see the clock tower of Philadelphia City Hall at night when mere days before I thought it was the moon.”

Ashley Carper, a mother of two children with the disorder, said treatment has allowed her 11-year-old son Cole to read large-print books and write his own homework. Previously he could only read with Braille. Cole said the improvements extend beyond schoolwork.

“I can stay out later when my friends are outside playing and now I feel like part of the group,” he said. “My vision is not perfect, but what I do have is still really important to me.”

Researchers tested the treatment by recording patients’ ability to complete an obstacle course at varying levels of light, simulating real-world conditions like navigating a dark stairwell. A hallmark of the inherited disorder is difficulty seeing a night. Patients with the mutation generally start losing their sight before age 18, almost always progressing to total blindness.

One year after treatment 18 out of 20 patients who received the injection showed the maximum improvement in completing the obstacle course, and 13 completed the task at the lowest level of light. None of the patients in a comparison group did.

Doctors deliver the therapy with an injection in each eye that inserts a replacement gene into the retina via a modified virus.

Philadelphia-based Spark Therapeutics hopes to use its technology to treat other retinal disorders, including one called choroideremia, which affects about three times as many people as the condition currently under FDA review. The company is also investigating therapies to treat the blood disorder hemophilia and diseases of the nervous system.

As a potential breakthrough therapy for a rare disease, much of the discussion around Luxturna has focused on its cost. Drugmakers often price similar drugs at $250,000 or more. Spark has not given an estimated cost, which companies usually announce only after approval. But the company’s stock ticker symbol “ONCE” reinforces the company’s hope that this will be a one-time treatment — and expense.

“It is the aspiration,” Spark Therapeutics CEO Jeff Marrazzo told The Associated Press prior to the meeting.

Pharmaceutical analyst Michael Yee estimates the drug will be priced between $350,000 and $450,000 per injection. He expects sales of $40 million to $50 million in 2018, growing to as much as $100 million in 2019.

Just Posted

Police informer talks about his role in Castor undercover sting

Jason Klaus and Joshua Frank were convicted of triple murders last month

City of Red Deer invites residents to Let’s Talk

Interactive public forum to be held April 7

Lessons in altruism learned by Red Deer students

St. Francis of Assisi School launches community foundation project

Sylvan Lake council approves fire pits and mobile stage

Large fire pits for group gatherings will be located on pier next winter

WATCH: Red Deer Taboo Show in full swing

The Red Deer Taboo Show is in full swing at Westerner Park.… Continue reading

Driver crashes into Red Deer business while fleeing police

A car smashed through a Red Deer business’ front window while fleeing… Continue reading

VIDEO: ‘New wave’ of anti-pipeline protests return to Trans Mountain facility

About 100 demonstrators with Protect the Inlet marched to the Burnaby terminal Saturday

Groups expressing concern about jobs funding rules await final decision

OTTAWA — It was Valentine’s Day when an Alberta church was told… Continue reading

Superstore chain Fred Meyer to stop selling guns, ammunition

PORTLAND, Ore. — Superstore company Fred Meyer will stop selling guns and… Continue reading

Wickenheiser says strengthening Olympic hockey bridge behind North Korea trip

CALGARY — Hayley Wickenheiser was conflicted about the unified Korean women’s hockey… Continue reading

Watch: Volcanic thunder is real, and this is what it sounds like

Behold, the rumble of volcanic thunder. No, this is not the sound… Continue reading

Cosmetics giant L’Oreal buys Toronto augmented reality startup ModiFace

TORONTO — When University of Toronto engineering professor Parham Aarabi first began… Continue reading

Most Read

Five-day delivery plus unlimited digital access for $185 for 260 issues (must live in delivery area to qualify) Unlimited Digital Access 99 cents for the first four weeks and then only $15 per month Five-day delivery plus unlimited digital access for $15 a month